BioCryst Pharmaceuticals, Inc. (BCRX)
7.63
-0.06
(-0.78%)
USD |
NASDAQ |
Nov 09, 16:00
7.70
+0.07
(+0.92%)
Pre-Market: 09:21
BioCryst Pharmaceuticals Cash and Short Term Investments (Quarterly) : 375.52M for Sept. 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 375.52M |
| June 30, 2026 | 353.05M |
| March 31, 2026 | 239.25M |
| December 31, 2025 | 274.95M |
| September 30, 2025 | 213.45M |
| June 30, 2025 | 260.53M |
| March 31, 2025 | 295.38M |
| December 31, 2024 | 321.06M |
| September 30, 2024 | 330.83M |
| June 30, 2024 | 273.82M |
| March 31, 2024 | 338.35M |
| December 31, 2023 | 390.79M |
| September 30, 2023 | 399.17M |
| June 30, 2023 | 412.24M |
| March 31, 2023 | 399.62M |
| December 31, 2022 | 425.78M |
| September 30, 2022 | 428.30M |
| June 30, 2022 | 418.93M |
| March 31, 2022 | 446.82M |
| December 31, 2021 | 510.95M |
| September 30, 2021 | 203.89M |
| June 30, 2021 | 222.78M |
| March 31, 2021 | 244.36M |
| December 31, 2020 | 302.59M |
| September 30, 2020 | 145.53M |
| Date | Value |
|---|---|
| June 30, 2020 | 191.59M |
| March 31, 2020 | 114.62M |
| December 31, 2019 | 137.78M |
| September 30, 2019 | 69.98M |
| June 30, 2019 | 96.78M |
| March 31, 2019 | 109.95M |
| December 31, 2018 | 106.01M |
| September 30, 2018 | 121.83M |
| June 30, 2018 | 88.36M |
| March 31, 2018 | 95.91M |
| December 31, 2017 | 117.68M |
| September 30, 2017 | 164.75M |
| June 30, 2017 | 86.03M |
| March 31, 2017 | 101.48M |
| December 31, 2016 | 56.20M |
| September 30, 2016 | 54.33M |
| June 30, 2016 | 40.17M |
| March 31, 2016 | 37.78M |
| December 31, 2015 | 53.18M |
| September 30, 2015 | 71.95M |
| June 30, 2015 | 95.93M |
| March 31, 2015 | 70.16M |
| December 31, 2014 | 72.92M |
| September 30, 2014 | 127.28M |
| June 30, 2014 | 132.26M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Amgen, Inc. | 13.19B |
| Halozyme Therapeutics, Inc. | 1.074B |
| Neurocrine Biosciences, Inc. | 737.90M |
| Agenus, Inc. | 86.94M |
| Anika Therapeutics, Inc. | 44.96M |